Market Overview

UPDATE: Loewen, Ondaatje, McCutcheon Initiates BioMimetic Therapeutics at Buy on Regulatory Tailwinds

Related BMTI
UPDATE: Wedbush Terminates Coverage on BioMimetic Therapeutics on Acquisition by Wright Medical
UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT

Loewen, Ondaatje, McCutcheon initiated its coverage on BioMimetic Therapeutics (NASDAQ: BMTI) with a Buy rating and a $7.50 price target.

Loewen, Ondaatje, McCutcheon commented, "BioMimetic Therapeutics is a development-stage regenerative medicine company focused on the $1+ billion orthobiologics market. Its lead product candidate is Augment which is designed as an alternative to autograft in foot and ankle fusion surgery. While Augment has endured a challenging regulatory review, the recently submitted PMA amendment provides us with a higher degree of confidence it will receive FDA approval."

BioMimetic Therapeutics closed at $3.82 on Wednesday.

Latest Ratings for BMTI

Mar 2013Wells FargoTerminatesNeutral
Nov 2012Loewen, Ondaatje, McCutcheonDowngradesBuyHold
Oct 2012Loewen, Ondaatje, McCutcheonInitiates Coverage onBuy

View More Analyst Ratings for BMTI
View the Latest Analyst Ratings

Posted-In: Loewen McCutcheon OndaatjeAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (BMTI)

View Comments and Join the Discussion!

Best & Worst ETFs & Mutual Funds: Consumer Staples Sector

UPDATE: McAdams Wright Ragen Downgrades StanCorp Financial Group to Hold on Limited Upside